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Rates of Down syndrome (DS) show considerable international
variation, but a systematic assessment of this variation is lacking.
The goal of this study was to develop and test a method to assess
the validity of DS rates in surveillance programs, as an indicator
of quality of ascertainment. The proposed method compares the
observed number of cases with DS (livebirths plus elective
pregnancy terminations, adjusted for spontaneous fetal losses
that would have occurred if the pregnancy had been allowed to
continue) in each single year of maternal age, with the expected
number of cases based on the best-published data on rates by year
of maternal age. To test this method we used data from birth
years 2000 to 2005 from 32 surveillance programs of the Inter-
national Clearinghouse for Birth Defects Surveillance and Re-
search. We computed the adjusted observed versus expected
ratio (aOE) of DS birth prevalence among women 25–44 years
old. The aOE ratio was close to unity in 13 programs (the 95%
confidence interval included 1), above 1 in 2 programs and below
1 in 18 programs (P< 0.05). These findings suggest that DS rates
internationally can be evaluated simply and systematically, and
underscores how adjusting for spontaneous fetal loss is crucial
and feasible. The aOE ratio can help better interpret and compare
the reported rates, measure the degree of under- or over-regis-
tration, and promote quality improvement in surveillance pro-
grams that will ultimately provide better data for research,
service planning, and public health programs.2010 Wiley-Liss, Inc.
Key words: Down syndrome; epidemiology; prevalence; validity;
registries
INTRODUCTION
Over the last several decades, national and international efforts
have led to the establishment of many birth defect registries and
surveillance programs worldwide [Dolk, 2005; Botto et al., 2006].
Although their specific goals vary, a shared objective of these
programs is to monitor the occurrence of birth defects and their
changes over time. Monitoring has many uses. It can detect clusters
or epidemics of birth defects, document the effectiveness of pre-
ventive interventions (as in the case of folic acid fortification to
prevent neural tube defects), and help estimate the burden of
disease when developing public health priorities. The usefulness
of such information is enhanced when shared by the program
within a country [Canfield et al., 2006; Kirby and Mai, 2006] or
internationally [Dolk, 2005; Botto et al., 2006], as promoted by the
International Clearinghouse for Birth Defects Surveillance and
Research (ICBDSR), which has member programs from North
America, South America, Europe, Middle-East, Far East, and
Oceania [Botto et al., 2006].
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For many birth defects, and for Down syndrome (DS) in parti-
cular, rates by country and surveillance program can vary consid-
erably. DS is in fact one of the most common birth defect evaluated
by surveillance programs [Stoll et al., 1994; Iliyasu et al., 2002; Dolk
et al., 2005; Metneki and Czeizel, 2005; Mosquera Tenreiro et al.,
2009], and its variation raises the issue of the validity of the findings
and the extent that the variation reflects problems in diagnosis,
ascertainment, and registration. In studies of DS, validation typi-
cally focuses on precision of clinical diagnosis or on completeness of
ascertainment and reporting. Validating the clinical diagnosis was
not the specific aim of this study, and would typically require
evaluating the completeness of cytogenetic diagnosis or the clinical
precision of expert clinical geneticists. In this study we focused on a
crucial epidemiologic aspect of validation, the completeness of
ascertainment and reporting. In a more general project to evaluate
the validity of birth defect rates, we focused on such epidemiological
validation of DS rates for several reasons. First, as mentioned, DS is
one of the most common birth defects monitored by many pro-
grams. Second, many cases can be diagnosed clinically in the
newborn period, more easily than for many common structural
birth defects (e.g., some heart and kidney malformations), so that
validity issues in rates of DS may suggest perhaps even greater
challenges in the ascertainment of other birth defects. Third, it is
recognized that in many countries, elective terminations of preg-
nancy have a considerable impact on the birth prevalence of many
birth defects including DS (particularly as maternal serum screen-
ing is increasingly recommended). Finally, data published over
the years suggest that rates of DS, once one accounts carefully for
spontaneous fetal losses after a prenatal diagnosis (SFL) and
maternal age, are fairly stable and constant across years and
countries [Carothers et al., 1999]. This fact provides a robust basis
to generate expected rates for DS, and support the choice of DS
when trying to assessing the validity of rates in a surveillance
program.
A common approach to validation of DS rates has been to use
active ascertainment from additional external data sources, with
or without statistical methods such as capture–recapture [Hook
and Regal, 1995; Campbell et al., 2002; Wang et al., 2006; Melve
et al., 2008; Savva and Morris, 2009]. This approach, however, can
be impractical for many programs, either because it can be costly
and difficult to perform or because high-quality external and
independent data sources may be unavailable.
We describe here in detail a simple and inexpensive method
to evaluate the validity of DS rates, which can be used in many
surveillance programs in developed and developing countries. We
used this method to examine rates from a recent cohort of births
with DS from 32 birth defects surveillance programs worldwide.
METHODS
Data Sources
We used data on DS collected by surveillance programs that
are members of the ICBDSR. For most programs we evaluated
births for the period 2001–2005, with the exception of Chile Maule
(time period, 2002–2005), Malta (1999–2007), USA Atlanta (2000–
2004), and USA Utah (2001–2006). Data on DS and on total births
for these years were requested by single-year maternal age intervals
and by birth outcome (stillbirths and livebirths). For elective
terminations of pregnancy after a prenatal diagnosis of DS
(thereafter named ETOP), where these were legal, the gestational
age at termination (<16 weeks; 16 weeks or more) was also
requested. Six surveillance programs (Chile Maule, Italy Campania,
Italy Lombardia, Italy Sicilia, Japan JAOG—Japan Association
Obstetric and Gynecology, Russia Moscow) could provide the
distribution by single year of maternal age for the cases of DS, and
by 5-year interval for all births. In such cases, for the three Italian
programs (Italy Campania, Italy Lombardia, Italy Sicilia) we esti-
mated the maternal age distribution of total births by single year
within each 5-year age group using the regional birth distribution
given by the Italian National Institute of Statistics (ISTAT, 2009),
whereas for Chile Maule, Japan JAOG, and Russia Moscow we used
5-year maternal age intervals.
The main characteristics of the surveillance programs are sum-
marized in Table I. Additional details of these surveillance programs
(e.g., reporting, coding) are available from the annual reports of
the ICBDSR [2009] and the National Birth Defects Prevention
Network [NBDPN, 2006], from the EUROCAT—European Sur-
veillance of Congenital Anomalies website (http://www.eurocat.
ulster.ac.uk/, Nov 27, 2009), and from selected publications from
individual surveillance programs [Mutchinick et al., 1988; Czeizel,
1997; Irgens, 2000; Castilla and Orioli, 2004; De Vigan et al., 2005;
Feldkamp et al., 2005; Wertelecki, 2006; Correa-Villasenor et al.,
2003; Lowry et al., 2007; Zhuchenko et al., 2008].
Study Design
The goal of the study was to estimate the observed versus expected
number of DS cases among livebirths. With perfect ascertainment
and in the absence of ETOP, the expected number of DS cases in a
population can be directly inferred from the maternal age specific
rates of livebirth with DS published by Hecht and Hook [1996],
specifically the ‘‘derived rates’’ in Table 2 of their article, which are
based on studies judged by the authors to have ‘‘near complete’’
ascertainment of livebirth cases of DS. These rates are modeled
rates and are very similar to those computed by Bray et al. [1998]
and by Morris et al. [2003]. Applying these rates to the maternal
age distribution of the underlying population would provide a
first estimate of the expected number of cases of DS in that
population.
Computing the number of observed livebirths with DS in a
registry would be straightforward, except for the presence of ETOP.
Summing all livebirths and ETOP is only a first approximation.
ETOP with DS cannot be directly summed to the livebirth cases
because some of the ETOP would have been lost as SFL if they had
been allowed to continue; a further adjustment is required. We used
the estimated rates of SFL in DS by single year of maternal age
(25–44 years) published by Savva et al. [2006] in their Table 1, and
applied these to the ETOP with DS reported in each surveillance
program. SFL rate between the time of chorionic villus sampling
(CVS) and birth were used to adjust for ETOP before 16 weeks
gestation; SFL rate between amniocentesis and birth were used to
adjust for ETOP at 16 weeks or more. The new adjusted number of
observed cases can then be computed (Table II, fourth column), to
include livebirths plus the fraction of ETOP that would have ended
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as livebirths if allowed to continue. Note that this adjustment is not
needed for programs where ETOP are illegal.
From these figures one can compute the adjusted observed versus
expected (aOE) ratio by maternal age. In this report we focused on
the maternal age range from 25 to 44 years because the published
data on SFL rates are available only for this age range. Also, this age
range includes most reported cases of DS, and the sample size in
many surveillance programs for ages outside of this range are
too small for precise estimations. The steps in computation, with
examples, are detailed in Appendix 1.
Statistical Methods
Adjusted observed versus expected ratios of livebirths with DS
were computed for each program for the age range 25–44 years
maternal age. We used the 95% confidence interval (CI) to
identify programs with potential under-registration (upper con-
fidence limit <1.0) or over-registration (lower confidence limit
>1.0). Statistical analyses were done with Stata software, version
10.0 [StataCorp, 2007]. Heterogeneity of the aOE ratios by 5-year
maternal age strata was evaluated using the Breslow–Day test
TABLE II. Down Syndrome Adjusted Observed–Expected (aOE) Ratio for the Maternal Age 25–44 years by International Clearinghouse for Birth
Defects Surveillance and Research (ICBDSR) Surveillance Programs (2001–2005)
Surveillance program Total births
Observed
total casesa
Observed
LB cases adjb
Expected
LB cases aOE 95% CI
Chile Maulec 30,250 106 105 82.4 1.27 1.04–1.54
Maltac 27,161 67 66 55.9 1.18 0.91–1.50
South America ECLAMC 508,889 1,474 1,440 1,296.5 1.11 1.05–1.17
Czech Republic 357,203 748 612 574.8 1.06 0.98–1.15
Sweden 412,552 1,175 1,014 972.8 1.04 0.98–1.11
Western Australia 97,751 303(1) 238 234.2 1.01 0.89–1.15
Finland 227,918 680 563 569.7 0.99 0.91–1.07
Australia Victoria 271,829 869(2) 680 689.6 0.99 0.91–1.06
Wales 107,598 296 250 253.6 0.98 0.87–1.11
Hungary 346,544 720 615 624.4 0.98 0.91–1.07
Canada Alberta 147,942 381 317 326.3 0.97 0.87–1.08
USA Utahc 189,151 348 320 354.1 0.90 0.81–1.01
Russia Moscowd 142,511 249 246 272.7 0.90 0.79–1.02
France REMERAe 226,741 587(3) 475 544.1 0.87 0.80–0.95
Ukraine 62,017 106 102 117.9 0.87 0.71–1.05
Ireland Dublin 91,644 221 204 246.7 0.83 0.72–0.95
USA Atlantac 176,598 396(4) 355 430.5 0.83 0.74–0.91
Norway 239,123 473 426 516.8 0.82 0.75–0.91
Slovak Republic 165,472 243 235 286.0 0.82 0.72–0.93
Germany Saxony Anhalt 59,001 112(5) 95 116.6 0.82 0.66–1.01
USA Texas 1,088,970 1,970 1,864 2,354.2 0.79 0.76–0.83
USA California 176,427 324(6) 304 392.5 0.77 0.69–0.87
Northern Netherlands 86,898 157(7) 139 185.2 0.75 0.63–0.89
Israel IBDSP 87,340 149 134 197.3 0.68 0.57–0.80
Mexico RYVEMCEd 58,961 84 81 121.9 0.66 0.53–0.83
Italy Emilia Romagna 141,842 314(8) 252 398.3 0.63 0.56–0.71
Italy Lombardia 39,994 64 57 106.3 0.54 0.40–0.69
Italy Sicilia 75,600 106 92 181.5 0.51 0.41–0.62
Italy Toscana 124,169 219 169 345.6 0.49 0.42–0.57
Italy Campania 225,142 317 264 544.3 0.49 0.43–0.55
Japan JAOG 363,966 396 377 819.6 0.46 0.41–0.51
Iran TRoCA 55,260 17 17 116.1 0.15 0.09–0.23
aOE, adjusted observed–expected ratio.
ECLAMC, Latin-American Collaborative Study on Congenital Anomalies; IBDSP, Israel Birth Defects Surveillance Program; JAOG, Japan Association Obstetric and Gynecology; REMERA,
Rhone-Alps Registry of Congenital Anomalies; RYVEMCE, Mexican Registry and Epidemiologica Surveillance of Congenital Malformations; TRoCA, Tabuz Registry of Congenital Anomalies.
aObserved (Obs) total cases include livebirths (LB), stillbirths (SB) and elective terminations of pregnancy.
bObserved livebirths cases adjusted (adj) include livebirths and elective terminations of pregnancy ‘‘adjusted’’ for spontaneous fetal losses for those surveillance programs
where elective terminations of pregnancy are permitted.
cAvailable years: Chile Maule, 2002–2005; Malta, 1999–2007; USA Utah, 2001–2006; USA Atlanta, 2000–2004.
dP-value for heterogeneity among the four 5-year maternal age groups.
eFifty-two elective terminations of pregnancy >24 week not computed in the adjustment for fetal losses.(1–8) Calculated by assuming that livebirths, stillbirths or elective
terminations of pregnancy of unknown maternal age had the same age distribution as those of known maternal age: (1) 2 cases of unknown maternal age, (2) 75 cases, (3) 66 cases,
(4) 1 case, (5) 4 cases, (6) 34 cases, (7) 2 cases, (8) 4 cases.
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[Breslow and Day, 1987], with a threshold for heterogeneity set at
P< 0.10.
RESULTS
For each surveillance program in the study, Table II shows the
number of births monitored by the program, the crude number of
observed DS cases (livebirths, stillbirths, ETOP), and the adjusted
number of DS livebirths taking into account the expected SFL (for
programs who report ETOP). The table also shows the expected
number of DS livebirths based on the published reference rates by
Hook et al. and the aOE ratios with the 95% CI. As noted in the
Methods Section, these data relate to the population of women
between 25 and 44 years of age. Figure 1 illustrates the range of aOE
and confidence intervals, sorted by descending aOE ratios.
Of the 32 programs, 13 had an aOE ratio consistent with 1 (i.e., 1
was included in the 95% CI of the aOE) and ranged from 1.18 to 0.82
(Malta, Czech Republic, Sweden, Western Australia, Australia
Victoria, Hungary, Wales, Canada Alberta, Finland, USA Utah,
Russia Moscow Region, Ukraine, and Germany Saxony Anhalt).
Two programs, both from Latin America (Chile Maule and
ECLAMC) had a statistically elevated aOE (1.27 and 1.11,
respectively) and 17 had a statistically decreased aOE (from 0.87
to 0.15). Statistical evidence of heterogeneity by maternal age strata
was noted in Mexico Mexican Registry and Epidemiological Sur-
veillance of Congenital Malformations (RYVEMCE) (P¼ 0.04)
and Russia Moscow (P¼ 0.03). In Mexico RYVEMCE, the aOE
ratio was close to 1 for maternal ages below 35 years, but low at
higher ages (0.57 in the 35- to 39-year group, and 0.32 in the 40- to
44-year groups). In Russia Moscow, the aOE was consistent at 0.75
in the age groups 25–29, 30–34, and 40–44 years, but increased
(1.33) in the in the 35- to 39-year maternal age group. All the other
30 registries did not show evidence of heterogeneity (P> 0.25).
DISCUSSION
In the present article we have described a novel, simple, and
inexpensive method to evaluate the validity of DS rates in birth
defects surveillance program. The method is based on the fairly well
-accepted assumption that maternal age-specific rates of DS are
unaffected by temporal, ethnic, geographical, or environmental
factors [Carothers et al., 1999]. Such stability of rates provide a
common, robust basis for estimating the expected theoretical
occurrence of DS in a surveillance program, once maternal age is
taken into account appropriately. Potential exceptions to the
stability of maternal age specific rates have been proposed, but not
conclusively demonstrated, for Israeli Jews of non-European origin
[Hook and Harlap, 1979], US-Hispanics [Hook et al., 1999], and
African Americans [Carothers et al., 1999]. Because of the similarity
of maternal age-specific rates across high-quality surveys in western
countries, these estimates are currently being used in many parts of
the world when calculating risks in prenatal screening programs for
DS [Hecht and Hook, 1996; Bray et al., 1998; Morris et al., 2003].
These rates, which have been estimated by single year of maternal
age, can be used to generate a ‘‘reference standard’’ for the expected
number of cases of DS within a surveillance program, once
the distribution of maternal age in the underlying population is
adequately known. The rate of SFL is also well known and can be
incorporated in the estimates of the expected rate. Differences
between the observed rate and the expected rate of DS may be due
one of two factors: (a) a methodological problem of the registry
(ascertainment, reporting, or registration); or (b) a real, biologically
meaningful difference in DS risk. Obviously the first possibility
must be strongly excluded before considering the second one.
Alternative methods can be used to evaluate the validity of DS
rates. Many are based on an active search of cases in the same
population, parallel or after reporting to the surveillance program,
[Metneki and Czeizel, 2005; Melve et al., 2008; Savva and Morris,
2009]. However, these methods can be expensive and time-inten-
sive, the data sources may not be available, and could themselves
have methodological problems (e.g., under-ascertainment, under-
registration, over-registration). The stability of rates of DS (by
single year of maternal age) is a special situation in which expected
rates can be computed with an unusually high degree of confidence.
When resources are lacking, the method we proposed may repre-
sent the only practical possibility to evaluate validity. Even when
resources are available for an additional active search of cases,
the proposed method is still recommended because it provides a
benchmark to measure the improvement due to the additional
search and can signal a potentially real increase of DS in that
population.
Using recent data from a large, international sample of surveil-
lance programs from the International Clearinghouse, we have
tested the method and shown the feasibility of a simple, novel
method to evaluate the validity of reporting of DS that takes into
account reported rates of ETOP and SFL, and that can be done
effectively at minimal cost.
We also report findings that highlight certain patterns of ascer-
tainment that can be valuable to know when using these data on DS
for public health research and policy. For example, in several
programs (13 in this study), the reported registration of DS among
livebirths appears to be valid, based on the adjusted OE ratio. This
was true even in the presence of marked variation in acceptance of
clinical diagnosis for registration (Table I), screening policies for
DS, and frequency of ETOP (data not shown, available on request).
For example, the frequency of reported ETOP ranged from none in
Malta (where ETOP are illegal), to fairly low in USA Utah (9%), to
very high in Western Australia (61%) and Czech Republic (68%),
suggesting that the methodology we used to adjust for the SFL is
reliable.
Possible Explanations for High and Low aOE Ratios
There are several possible explanations for why some programs
appear to over-register or under-register DS cases among livebirths.
Over-registration (suggested by statistically elevated aOE ratios)
is difficult to explain. It could be due to errors in coding or to
random variation. For example, the highest aOE in the study was
found in Chile-Maule (aOE 1.27; 95% CI 1.04–1.54), but it appears
that DS rates are lower when considering a longer period of
observation [Canessa, unpublished work, May 2009]. Selection
bias is another possibility. For example, the other statistically
significant increased aOE ratio was observed in South America
ECLAMC (aOE 1.11, 95% CI 1.05–1.17). A similar finding was
LEONCINI ET AL. 1675
reported previously in this program [Carothers et al., 2001] in that
reported rates (actually, observed vs. expected index values, similar
to aOE ratios) were found to increase over time, from 1967 to 1997.
A selection bias could occur in principle if fetuses identified
prenatally with a condition associated with DS (e.g., nuchal trans-
lucency, heart defect, duodenal atresia) were then referred to the
select group of hospitals included in the hospital-based surveillance
program. This hypothesis was also suggested by ECLAMC staff
when interpreting the finding of an apparent cluster of oral clefts in
the program [Poletta et al., 2007]. Alternatively, the increase may be
real, if in fact women of Hispanic ethnicity have higher rates of DS-
affected pregnancies [Carothers et al., 1999; Canfield et al., 2006].
FIG. 1. Down syndrome adjusted observed–expected (aOE) ratio for the maternal age 25–44 years among 32 surveillance program members of the
International Clearinghouse for Birth Defects Surveillance and Research—ICBDSR (2001–2005). Note to the figure: ECLAMC, Latin-American
Collaborative Study on Congenital Anomalies; IBDSP, Israel Birth Defects Surveillance Program; JAOG, Japan Association Obstetric and Gynecology;
REMERA, Rhone-Alps Registry of Congenital Anomalies; RYVEMCE, Mexican Registry and Epidemiologic Surveillance of Congenital Malformations;
TRoCA, Tabriz Registry of Congenital Anomalies.
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Low aOE ratios, observed in the other 17 surveillance pro-
grams, suggest the possibility of under-registration. Of these pro-
grams, one (Norway) has published a validation study for DS of
cases registered in the year 2001–2005 using the alternative method
of active search of cases in external sources [Melve et al., 2008]. In
this program, the method estimates a sensitivity of 81% (95 CI
78.3–84.6%), which is very close to the 0.82 aOE ratio in the current
report (95% CI 0.75–0.91). This unique comparison between
methods is very helpful, and the concordance between the findings
is encouraging. Another surveillance program (USA Atlanta) pub-
lished their evaluation of the program’s ascertainment sensitivity
for birth defects as a group for the year 1995 [Honein and Paulozzi,
1999] and their finding (sensitivity of 86.9%; 95% CI 80.6–91.9%)
agrees well with the aOE ratio for DS in this report (aOE, 0.83; 95 CI,
0.74–0.91). This finding suggests that the validity of DS prevalence
may be a useful indicator of the validity of ascertainment for at least
some other birth defects in the same program.
Under-registration may be an issue in programs, such as in the
Netherlands, in which written informed consent is required for
inclusion in the surveillance programs. A recent study from the
Netherlands [Weijerman et al., 2008] reported a prevalence of
liveborn children with DS of 16 per 10,000 for 2003. By comparison,
the reported rate in the present study from the Northern Nether-
lands was 11.5 per 10,000 (113/98,579). This rate is 29% lower than
in the other Dutch study and, again, is consistent with the 25%
estimate of under-registration based on the aOE ratio (aOE¼ 0.75,
95% CI 0.63–0.89) computed with the method here described.
In countries where ETOP are illegal, as in Ireland, but likely
still occur (there is anecdotal evidence of women traveling abroad
for ETOP), one would expect some degree of under-ascertainment,
reflected in a low aOE ratio (in Ireland, aOE¼ 0.83). Perhaps
related to this issue is the finding from Mexico RYVEMCE that
the aOE ratios were low only in women above 35 years of age. This
could occur if prenatal diagnosis was done more intensively in
this age group, followed by illegal or unrecorded ETOP. In fact, the
number of illegal and unreported ETOP in Mexico is estimated to
be very high [Juarez et al., 2008]. In Japan, the very low aOE (0.46,
95% CI 0.41–0.51) is likely due to the hospital-based structure of
the program, which does not capture ETOP.
Of note is also the finding of consistently low aOE ratios in all
five surveillance programs from Italy (range, 0.49–0.63). There
could be two possible explanations: (a) ETOP with DS could be
under-reported, particularly for diagnosis occurring early in preg-
nancy or done outside the program’s catchment area; (b) livebirths
with DS could be under-reported, as suggested by a recent analysis
in Italy Campania in 2006 where comparing registry and hospital
discharge data indicated a 67% under-notification of livebirths with
DS to the registry [Scarano, unpublished data, May 2009].
Some US programs (Atlanta, California, Texas), although not all
(Utah), have low aOE ratios, and the reason for this finding is
unclear. It could be due in part to missed ETOP, either because they
occurred outside of the program’s catchment areas or in clinics not
part of the ascertainment system. Utah may have better ascertain-
ment because of its intensive program, lower rate of ETOP, and the
statewide structure of the program. Whether or not ethnic back-
ground influences the lower reported rates from the three programs
is unclear. Some reports suggest that persons of African American
background have lower rates of DS [Carothers et al., 1999], and that
persons of Hispanic ethnicity have higher rates [Hook et al., 1999],
but this would only amplify the extent of under-reporting at least in
California and Texas, where the proportion of Hispanic women is
high.
Strengths and Limitations
Strengths of this analysis include the large and varied sample of
surveillance programs, the use of careful adjustment by maternal
age (single year), the incorporation of estimates of SFL, and the
focus on the age range where most cases occur (25–44 years) and
therefore less influenced by random variations due to small sample
size. Evaluating DS rates by single year of maternal age is crucial to
minimize confounding by maternal age, which can be a major factor
when comparing populations with different maternal age distri-
butions [Hecht and Hook, 1994]. Adjustment for SFL is also imp-
ortant, since in some areas a large proportion of DS pregnancies is
diagnosed prenatally and many pregnancies are terminated. Fo-
cusing on the maternal age range from 25 to 44 years provides a well-
characterized, large sample of pregnancies for which reference
standards for maternal age and SFL are available and robust.
Limitations include the use of 5-year (instead of single year)
maternal age intervals in six registries. We were able to obtain finer
estimates in three Italian surveillance programs using regional data
from official statistics. To evaluate this process, in some programs
(Italy Tuscany, Italy Emilia Romagna, Norway, and Finland), we
were able to use both methods and observed very similar results.
Another limitation was the use of week ranges, rather than the exact
week, of the time of prenatal diagnosis. For the timing of ETOP we
had available only two categories (<16 weeks; 16 weeks or more).
For programs in which there typically may be a long gap between
diagnosis and ETOP (particularly for late ETOP, between 20 and
24 weeks), our method would have over-adjusted for SFL. If so, the
effect is likely quite small. In the France Rhone-Alps Registry
of Congenital Anomalies (REMERA), we did not adjust for the
52 TOP cases terminated after 24 weeks of gestation. Finally,
another potential limitation is that published reference data for
single-year maternal age DS rates and for SFL rates are available only
for Western white women. When specific data become available for
other racial-ethnic groups, these can easily be incorporated in the
analysis.
Conclusions and Implications
Evaluating the validity of birth defects data is crucial for the app-
ropriate use of these data in clinical and public health research and
policy. As birth defects as a group become an increasingly important
driver of pediatric morbidity and mortality, the need for accurate,
valid data also increases. Birth defects surveillance programs are a
key and sometimes only source for these data, but typically operate
with limited resources. Validity studies as those presented in this
report help focus on areas of improvement, where additional
resources and support are needed to improve data collection and
data quality.
One benefit of the approach proposed here is that it requires
only limited additional effort and can be used in any surveillance
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program where the distribution of cases and total births by single
maternal age is available. Adjusting for SFL is essential in those
surveillance programs where ETOP are allowed and common. This
approach provides a single, simple parameter (adjusted OE ratio)
that can help to better interpret rates, estimate the degree of under-
and over-registration of cases, and compare programs nationally
and internationally. In turn, this information can be a starting point
to help to improve surveillance programs and ultimately promote
the appropriate use of data for public health. To the extent that DS
registration reflects the more general operation of a surveillance
program, the validity of DS registration may be also a good initial
indicator of the accuracy of data on other birth defects in surveil-
lance programs.
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